Prosonix appoints first head of regulatory affairs

Prosonix, an emerging UK-based pharmaceutical company developing respiratory medicines, has appointed Rob Crocker as its first head of regulatory affairs.

Crocker has more than 20 years’ experience in pharmaceutical regulatory affairs and drug development, with significant expertise in generic respiratory and inhaled medicines. Since 1999, he has been managing director of PhRAction (formerly Pharmaxis), a pharmaceutical regulatory affairs and drug development consultancy, where he was responsible for 10 submissions of orally inhaled drug products to international regulatory agencies.

Before that, he held senior drug development regulatory affairs positions at Boehringer Ingelheim, Ethical Generics (now Genus Pharmaceuticals), Trinity Pharmaceuticals (now Trinity Chiesi), Norton Healthcare (now Teva EU) and Glaxo Group Research (now GSK).

Crocker is a member of The Organisation for Professionals in Regulatory Affairs (TOPRA).

Commenting on the appointment, David Hipkiss, Prosonix’ ceo, said: ‘We recently announced the formation of a new Scientific Advisory Board and we are also building our expertise in regulatory affairs and clinical development. Rob’s appointment is the next step and we expect his regulatory expertise, particularly submissions for generic respiratory medicines, to be crucial given our plans to file PSX1001, our leading drug candidate, for asthma in late 2012. We also expect him to play an important role in the planning and execution of our regulatory and clinical development strategies for PSX1002 and the PSX2000 series of combination medicines.’